The strategic oncology partnership between Oxford BioTherapeutics and Berlin Chemie/Menarini Group has designated its second clinical development candidate: a novel antibody-drug conjugate (ADC) targeting Non-Hodgkin’s B-Cell Lymphoma and solid tumours, including some subsets of breast cancers. The ADC is currently undergoing formal regulatory enabling studies to support an application for the future clinical phase. The ADC candidate has completed in vivo proof-of-concept in several solid and liquid tumour models and exploratory toxicology testing.